NCT07137338View on ClinicalTrials.gov

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2026

Primary Completion Date

June 30, 2029

Study Completion Date

June 30, 2029

Conditions
Dilated Cardiomyopathy (DCM)
Interventions
GENETIC

RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

One-time treatment with a single ascending dose

All Listed Sponsors
lead

Rocket Pharmaceuticals Inc.

INDUSTRY